Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/LSD/Substance Use Disorders (SUD)

LSD for Substance Use Disorders (SUD)

108 papers and 3 clinical trials exploring lsd as a treatment for substance use disorders (sud).

Compoundclassic psychedelic

LSD

LSD is a classic psychedelic ergoline with high potency at microgram doses and an 8-12 hour duration of action, mediated primarily via 5-HT2A receptor agonism. Modern Phase IIb data in generalised anxiety disorder and FDA Breakthrough Therapy Designation for MM120 have reignited clinical development.

Full LSD profile
IndicationOver 2% of the global population is affected by some form of substance use disorder, contributing to nearly 12 million deaths annually.

Substance Use Disorders (SUD)

Substance use disorders (SUDs) are complex conditions marked by compulsive substance use despite negative consequences. Recent research is exploring the therapeutic potential of various psychedelics, including LSD, psilocybin, and MDMA, in treating these disorders to provide novel, effective treatment options.

Full Substance Use Disorders (SUD) profile

Academic Research

108 papers
Paywallindividual

A qualitative analysis of participant expectations and experiences of psilocybin-assisted psychotherapy for methamphetamine use disorder

Participants in a pilot study of psilocybin‑assisted psychotherapy for methamphetamine use disorder found the intervention acceptable and reported that confronting vividly challenging psychedelic experiences—described as “leaning into the obstacle”—fostered new self‑understandings and shifts in relationships that reduced the salience of methamphetamine. A strong therapeutic alliance, characterised by concentrated attention and intersubjective intimacy, was seen as critical to these positive changes.

Published
December 22, 2025
Journal
Addiction
Authors
Brett, J., Lea, T., Knock, E., Albert, S., Acheson, L., Siefried, K. J., Job, S.
Paywallindividual

Single Treatment With MM120 (Lysergide) in Generalized Anxiety Disorder: A Randomized Clinical Trial

In a multicentre phase 2b randomised placebo‑controlled trial of 198 adults with moderate to severe GAD, a single dose of MM120 (lysergide D‑tartrate) produced a dose‑dependent reduction in HAM‑A scores at 4 weeks, with 100 µg and 200 µg showing significant improvements versus placebo (least‑squares mean differences −5.0 and −6.0 points, respectively). Adverse events were dose‑related—most commonly visual perceptual changes and nausea—supporting the efficacy and informing dose selection for phase 3 trials.

Published
October 21, 2025
Journal
JAMA
Authors
Robison, R., Barrow, R., Conant, C., Foster, E., Freedman, J. M., Jacobsen, P. L., Karas, S. M., Karlin, D. R., Solomon, T. M., Wernli, M. H., Fava, M. F., Jemisen, J.
Open Accessindividual

Health-related behavioral changes following the use of psychedelics in naturalistic settings

This cross-sectional study (n=2,510) of US adults with psychedelic experience found that participants retrospectively reported widespread improvements in health behaviours including reduced alcohol (66%) and tobacco (49%) use, better dietary habits (49%), and decreased impulsivity (48-72%), with microdosers and frequent users showing greater positive changes.

Published
August 1, 2025
Journal
Preventative Medicine Reports
Authors
Teixeira, P. J., Jain, R., Penn, A. D., Cole, S. P., Jain, S., Moller, A. C., Amaro, H., Raison, C.
Paywallindividual

The polypharmacology of psychedelics reveals multiple targets for potential therapeutics

This receptor profiling study (n=41 compounds) maps the pharmacological activity of classical psychedelics across 318 human G-protein-coupled receptors and, for LSD, over 450 human kinases. It finds that psychedelics act potently at nearly all serotonin, dopamine, and adrenergic receptors, with multiple 5-HT2A receptor signalling pathways linked to psychedelic effects in vivo.

Published
July 15, 2025
Journal
Neuron
Authors
Jain, M. K., Gumpper, R. H., Slocum, S. T., Gloriam, D. E., Nichols, D. E., Roth, B. L., Schmitz, G. P., Madsen, J. S., Tummino, T. A., Suomivuori, C. M., Huang, X. P., Shub, L., Diberto, J. F., Kim, K., Deleon, C., Krumm, B. E., Fay, J. F., Keiser, M., Hauser, A. S., Dror, R. O., Shoichet, B.
Open Accessindividual

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

This double-blind randomised clinical trial (n=37) found that a single dose of psilocybin (25mg) with brief psychotherapy did not significantly reduce alcohol relapse rates or consumption compared to placebo in patients with alcohol use disorder (AUD) at 4-week or 6-month follow-up, though psilocybin participants reported additional reductions in craving and temptation to drink, suggesting larger trials are needed to evaluate this approach for severely affected patients.

Published
April 1, 2025
Journal
EClinicalMedicine
Authors
Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., Preller, K. H.
Open Accessmeta

Insights on Psychedelics: A Systematic Review of Therapeutic Effects

This systematic review (s=98) examining psychedelic-catalysed insight found that 86% of studies showed insight was linked to therapeutic improvement, with insight being dose-dependent and significantly higher than placebo in 93% of comparative studies, suggesting insight may be a key mechanism in psychedelic therapy.

Published
March 22, 2025
Journal
Neuroscience and Biobehavioral Reviews
Authors
Kugel, J., Laukkonen, R., Yaden, D. B., Yücel, M., Liknaitzky, P.

Clinical Trials

3 trials
RecruitingPhase II

LSD Treatment for Persons With Alcohol Use Disorder (LYSTA)

Double-blind, randomised, active placebo-controlled parallel study (n=126) testing two LSD doses (150 µg; second session 150 or 250 µg) versus low-dose active placebo (10 µg) for alcohol use disorder.

Started
January 1, 2023
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05474989
CompletedPhase NA

A clinical study of LSD treatment in alcoholism

Randomized controlled three-year investigation comparing three LSD treatment conditions (hypnodelic, psychedelic, and drug-alone) against a milieu therapy control in 176 male alcoholic inpatients at Mendota State Hospital, Wisconsin. All groups improved significantly across all follow-up periods; no LSD condition outperformed the control.

Started
January 1, 1966
Type
interventional
Blinding
single
Randomized
Yes
Completed

Single Oral Lysergide (LSD 500 µg) in Inpatient Alcoholic Rehabilitation: Controlled Evaluation with Schizophrenic Sub-Analysis (Tomsovic & Edwards 1970)

This unregistered trial (n=75) was a partially randomised, placebo-controlled evaluation of a single 500 µg oral dose of LSD for alcohol use disorder in an inpatient rehabilitation setting, which found higher abstinence rates in non-schizophrenic participants at one year.

Started
January 1, 1966
Type
interventional
Blinding
single
Randomized
Yes
Registry ID
TOMSOVIC-1970-QJSTUDIALCOHOL-LYSERGIDE-ALCOHOLICS

Explore further

Search all LSD papers Search all Substance Use Disorders (SUD) trials Full LSD profile Full Substance Use Disorders (SUD) profile